BRAF and malignant colon neoplasm: Accordingly, JACKS’ estimated BRAF essentiality in the Avana data set is large in BRAF mutant melanoma lines, weak in BRAF-mutant colon cancer lines, and negligible in most other lines (median, −1.39 vs. −0.35 vs. 0.03) (Fig. 3D), regardless of the data set used in estimation.